<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92466">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975454</url>
  </required_header>
  <id_info>
    <org_study_id>TCM-mCRC</org_study_id>
    <secondary_id>LHYY-11495801300</secondary_id>
    <nct_id>NCT01975454</nct_id>
  </id_info>
  <brief_title>Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer</brief_title>
  <official_title>A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chongqing Three Gorges Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: Science and Technology Commission of Shanghai Municipality</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Teng-Long-Bu-Zhong-Tang (TLBZT) is a modern anti-cancer herbal formula. Experimental studies
      have confirmed the anti-cancer potential of TLBZT against colorectal cancer. This trial will
      evaluate the safety and efficacy of TLBZT based herbal therapy in combination with
      chemotherapy in patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive chemotherapy until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal therapy plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_label>Herbal therapy plus chemotherapy</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herbal therapy</intervention_name>
    <description>TLBZT based herbal decoction administered orally twice a day</description>
    <arm_group_label>Herbal therapy plus chemotherapy</arm_group_label>
    <other_name>Traditional Chinese Medicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum with non-resectable
             metastatic disease;

          -  Ages between 18 and 70 years;

          -  Measurable lesion;

          -  Karnofsky Performance Status ≥ 60%;

          -  Estimated life expectancy of at least 6 months;

          -  Participants have no major organ dysfunction and chemotherapy contraindications:
             hemoglobin ≥90g/L, N &gt; 1.5×10^9/L, PLT≥ 100×10^9/L, normal liver and kidney function;

          -  Informed consent from the patient.

        Exclusion Criteria:

          -  Symptomatic brain metastasis;

          -  Adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months;

          -  Serious disease of heart, liver, kidney with severe dysfunction;

          -  Serious complications, such as gastrointestinal tract obstruction and hemorrhage;

          -  Pregnancy or breast-feeding women;

          -  Mental or cognitive disorders;

          -  Be participating other drug trials;

          -  Who are allergic to the study drug.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Hu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital, Shanghai University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gang Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Three Gorges Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Hu, MD, PhD</last_name>
    <phone>86-21-64385700</phone>
    <email>beearhu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Deng S, Hu B, An HM, Du Q, Xu L, Shen KP, Shi XF, Wei MM, Wu Y. Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5--Fluorouracil in CT26 colon carcinoma. BMC Complement Altern Med. 2013 Jun 8;13:128. doi: 10.1186/1472-6882-13-128.</citation>
    <PMID>23758730</PMID>
  </reference>
  <reference>
    <citation>Hu B, An HM, Shen KP, Du Q. [Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174-T cells and the mechanism]. Zhong Xi Yi Jie He Xue Bao. 2010 Nov;8(11):1048-52. Chinese.</citation>
    <PMID>21078269</PMID>
  </reference>
  <reference>
    <citation>Hu B, An HM, Shen KP, DU Q. [Effects of Tenglong Buzhong Decoction on proliferation and apoptosis of human colon carcinoma cell line LS174T]. Zhong Xi Yi Jie He Xue Bao. 2010 Jun;8(6):575-80. Chinese. Erratum in: Zhong Xi Yi Jie He Xue Bao. 2011 Mar;9(3):241.</citation>
    <PMID>20550881</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Traditional Chinese Medicine (TCM)</keyword>
  <keyword>Teng-Long-Bu-Zhong-Tang</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
